PREVANTICS SWAB
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PREVANTICS SWAB (PREVANTICS SWAB).
PREVANTICS SWAB is a topical antiseptic containing chlorhexidine gluconate. Its mechanism involves disruption of microbial cell membranes, leading to leakage of intracellular contents and cell death. It is effective against a broad spectrum of gram-positive and gram-negative bacteria, fungi, and some viruses.
| Metabolism | Chlorhexidine gluconate is not significantly metabolized; it is excreted unchanged in feces and urine after systemic absorption. Topical application results in minimal systemic absorption. |
| Excretion | Primarily renal excretion of unchanged drug (70-80%); approximately 20% undergoes hepatic metabolism with biliary/fecal elimination of metabolites. |
| Half-life | Terminal elimination half-life is 1.5-2 hours in patients with normal renal function; extends to 6-10 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment. |
| Protein binding | Approximately 20% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is 0.3-0.4 L/kg, indicating distribution primarily into extracellular fluid; minimal intracellular penetration. |
| Bioavailability | Systemic bioavailability after topical application is less than 1% due to minimal percutaneous absorption. |
| Onset of Action | Rapid bactericidal effect within 30 minutes of topical application; systemic absorption negligible with topical use. |
| Duration of Action | Bactericidal activity persists for 4-6 hours after a single application; clinical effect maintained with twice-daily dosing. |
Apply topically once daily to affected areas.
| Dosage form | SWAB |
| Renal impairment | No renal adjustment required due to negligible systemic absorption. |
| Liver impairment | No hepatic adjustment required due to negligible systemic absorption. |
| Pediatric use | Apply topically once daily to affected areas; safety in children <2 years not established. |
| Geriatric use | Same as adult dosing; no specific adjustments needed. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PREVANTICS SWAB (PREVANTICS SWAB).
| Breastfeeding | Unknown if excreted in human breast milk. Due to low systemic absorption after topical application, risk to nursing infant is likely minimal. Use with caution in breastfeeding women. No M/P ratio available. |
| Teratogenic Risk | No human data; animal reproduction studies not conducted. Given topical application with minimal systemic absorption, risk of teratogenicity is considered negligible across all trimesters. However, use only if clearly needed and after assessing risk-benefit. |
| Fetal Monitoring |
■ FDA Black Box Warning
Avoid contact with eyes, ears, and mucous membranes. May cause ototoxicity if instilled into ears with perforated eardrums. Do not use on open wounds or burns. Hypersensitivity reactions, including anaphylaxis, have been reported.
| Serious Effects |
Hypersensitivity to chlorhexidine or any component of the formulation. Use in eyes, ears (especially with perforated tympanic membrane), or on meninges. Use in infants less than 2 months of age (risk of skin irritation and systemic absorption).
| Precautions | Avoid contact with eyes, ears, and mouth. Do not use on mucous membranes. May cause skin irritation or allergic contact dermatitis. Use with caution in patients with known hypersensitivity to chlorhexidine. Prolonged use may lead to bacterial resistance. |
Loading safety data…
| No specific monitoring required beyond standard obstetric care. Observe for local skin reactions or signs of systemic toxicity (unlikely with topical use). |
| Fertility Effects | No human data on fertility impairment. Animal fertility studies not performed. Considered unlikely to affect fertility due to minimal systemic absorption. |